Joseph G Low

US Patent:

6972298, Dec 6, 2005

Filed:

May 9, 2002

Appl. No.:

10/144315

Inventors:

Vijaykumar M. Baragi - Ann Arbor MI, US
Madhav Narasimha Devalaraja - Ann Arbor MI, US
Joseph Edwin Low - Brighton MI, US
Vaishalee A. Padgaonkar - Livonia MI, US

Assignee:

Warner-Lambert Company - Ann Arbor MI

International Classification:

A61K031/41
A61K031/35
A61K031/165

US Classification:

514382, 514453, 514619

Abstract:

The present invention provides a method of treating or preventing neutrophil chemotaxis. Specifically, the present invention provides a method of treating or preventing neutrophil migration by administering to a patient a MEK inhibitor.

US Patent:

7108852, Sep 19, 2006

Filed:

Feb 23, 2001

Appl. No.:

09/885259

Inventors:

Madhav N. Devalaraja - Ann Arbor MI, US
Joseph E. Low - Ann Arbor MI, US

Assignee:

Warner-Lambert Company LLC - Morris Plains NJ

International Classification:

A61K 39/395
A61K 39/00

US Classification:

4241301, 4241841, 4241417

Abstract:

A hematopoetic factor called “colony stimulating factor” (CSF) is capable of synergizing the attracting capabilities of chemokines and of inducing the accumulation and/or activation in vitro and in vivo of key components of inflammatory responses. Various types of agents that inhibit or otherwise hinder the production, release or activity of CSF could be used therapeutically in the treatment of ischemia and other inflammatory diseases, such as autoimmune disease, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.

US Patent:

20070059280, Mar 15, 2007

Filed:

Sep 12, 2006

Appl. No.:

11/519502

Inventors:

Madhav Devalaraja - Ann Arbor MI, US
Joseph Low - Ann Arbor MI, US

International Classification:

A61K 38/20
A61K 38/19
A61K 39/395

US Classification:

424085100, 424145100, 424085200

Abstract:

A hematopoetic factor called “colony stimulating factor” (CSF) is capable of synergizing the attracting capabilities of chemokines and of inducing the accumulation and/or activation in vitro and in vivo of key components of inflammatory responses. Various types of agents that inhibit or otherwise hinder the production, release or activity of CSF could be used therapeutically in the treatment of ischemia and other inflammatory diseases, such as autoimmune disease, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.

US Patent:

54261139, Jun 20, 1995

Filed:

Apr 8, 1994

Appl. No.:

8/224891

Inventors:

Joseph E. Low - Brighton MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 3141
A61K 3138

US Classification:

514381

Abstract:

Tetrazol-benzothiophenes carboxamides or a pharmaceutically acceptable salt thereof are useful in preventing ulcer formation caused by nonsteroidal antiinflammatory drugs in mammals.